Previous 10 | Next 10 |
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1 option payments as well as potential development, regulatory, and commercial milesto...
CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management’s presentation at the upcoming investor con...
CAMBRIDGE, Mass., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced plans to host its fourth quarter and full year 2018 financial...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
The next few years are going to seriously challenge the skills of H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not t...
Axovant Sciences Ltd ( AXON ) is approaching two key catalysts which may attract the attention of the markets. When I last wrote about the company , I noted that I didn't like the decisions being made at AXON. Throughout 2019 we may begin to see if the company's risky decision, to pivot into ...
I have been pretty consistently bullish on Neurocrine ( NBIX ) for a while, but one of my more frequent criticisms has been a relatively spartan pipeline. Where some biotechs will throw numerous compounds into trials in the hopes that something “sticks”, Neurocrine has been far...
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The Dow Jones Industrial Average was up 0.21 percent to close at 24,579.96, led higher by 3M and...
Gainers: OncoCyte (NYSEMKT: OCX ) +228% . Voyager Therapeutics (NASDAQ: VYGR ) +36% . Conatus Pharmaceuticals (NASDAQ: CNAT ) +34% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +33% . HyreCar (NASDAQ: HYRE ) +21% . Sanmina (NASDAQ: SANM ) +18% . Woodward (NASDAQ: WWD ) +17% . J &a...
OncoCyte (NYSEMKT: OCX ) +132% on lung cancer liquid biopsy test results . More news on: OncoCyte Corporation, Voyager Therapeutics, Sanmina Corp, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...